Lupin announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD

Global pharma major Lupin Limited (Lupin) announced today that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva® (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.

Tiotropium Bromide Inhalation Powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with COPD.

"This approval of the first generic for Tiotropium Bromide Inhalation Powder by Health Canada underscores our commitment to bring affordable options of complex products for patients in Canada, particularly in the respiratory therapeutic area," said, Dr. Sofia Mumtaz, President - Legal, Canada, Australia, and Japan.

Tiotropium Bromide Inhalation Powder (RLD Spiriva®) had estimated annual sales of USD 42 million in Canada (IQVIA MAT Q4 of 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 805.45 as compared to the previous close of Rs. 779.65. The total number of shares traded during the day was 67976 in over 2910 trades.

The stock hit an intraday high of Rs. 811.10 and intraday low of 780.00. The net turnover during the day was Rs. 54414612.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 LupinPharmaCanada Approval HealthCanada Spiriva